Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:

NCT ID: NCT03167372 Not yet recruiting - Depression Clinical Trials

Pilot N-of-1 Light Therapy Study

Start date: July 2017
Phase: N/A
Study type: Interventional

This study compares the effect of two N-of-1 trials on study compliance with an N-of-1 protocol and on satisfaction with participation in an N-of-1 trial. Using within-person analyses, the study also compares the effect of different types of light therapy on mood, fatigue, sleep, physical activity, and side effects within a mild to moderately depressed cancer survivor population. Twenty participants will be randomized to the bright white versus dim red light therapyN-of-1 trial, while the remaining 10 participants will be randomized to a dim white versus dim red light comparator N-of-1 trial.

NCT ID: NCT03155516 Recruiting - Pain Clinical Trials

Effect of Good Pain Management (GPM) Ward Program on Moderate to Severe Cancer Pain Patients

GPM
Start date: August 30, 2016
Phase: N/A
Study type: Interventional

This study aims to set up a standardized cancer pain ward - known as the Good Pain Management (GPM) Ward with streamlined assessment and management procedures to act as a pain management model. In particular, it will enforce regular pain assessment from and throughout hospital admission, and treatment protocols introducing the use of strong-opioids in moderate cancer pain patients, following National Cancer Care Network (NCCN) Adult Cancer Pain Guidelines. The GPM ward will be compared against current-practice controlled ward.

NCT ID: NCT03154671 Not yet recruiting - Cancer Clinical Trials

Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer

Start date: July 1, 2017
Phase: N/A
Study type: Interventional

A multicentre two-group parallel single-blind (outcome assessor) randomized controlled trial (RCT). A cost effectiveness study alongside a clinical trial using a payer and societal perspective to study the cost-effectiveness of geriatric assessment and management compared to usual care will be conducted. Participants allocated to the control group will receive usual oncology care. Participants allocated to the intervention group will receive a comprehensive geriatric assessment and management in addition to their usual oncology care. The intervention will take 6 months to be completed. Total study follow-up will be 12 months for each participant.

NCT ID: NCT03153618 Not yet recruiting - Cancer Clinical Trials

VALIDATE: Virtual Agent Linked Intelligent Disease Assessment Tool Engine

VALIDATE
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

The collection and analysis of family, medical, lifestyle, and environmental exposure history (a Comprehensive Health History or "CHH") can identify critical risk factors for many chronic and life-threatening conditions, including cancer. Despite its importance, CHH is infrequently documented and analyzed in primary-care medical practice due to numerous hurdles, and currently available tools have proven inadequate to address this critical problem. This study will evaluate the Virtual Agent Linked Intelligent Disease Assessment Tool Engine ("VALIDATE") system as an easy to administer, accurate, cost-effective, and clinically useful tool for collecting and analyzing structured CHH data.

NCT ID: NCT03151291 Recruiting - Cancer Clinical Trials

Effects of WB-EMS and Specific Dietary Supplements on Cancer Patients

Start date: December 2016
Phase: N/A
Study type: Interventional

Patients suffering from cancer often experience a loss of muscle mass and strength during disease and its therapy. Muscle wasting is the main characteristic of the so-called cancer cachexia syndrome and responsible for many therapy-related complications and a poorer prognosis of the patient. Stabilizing muscle mass should therefore be a great goal in cancer care. Physical exercise and nutrition are promising measures to combat cancer-related muscle atrophy but conventional exercise programs may not always be suitable for physical-weakened patients and increased catabolic processes are difficult to overcome by normal Nutrition - especially in advanced cancer. Therefore, the present study aims to test a combined approach of specific nutritional supplementation and exercise using the novel strength training method of Whole-Body electromyostimulation (WB-EMS). The study investigates the effect of a 12-week WB-EMS training combined with a dietary supplementation of β-hydroxy-β-methylbutyrate (HMB), L-carnitine (LC) or the omega-3-fatty acid eicosapentaenoic acid (EPA) on skeletal muscle mass, body composition, physical function, nutritional and inflammatory status, fatigue and quality of life in cancer patients undergoing oncological treatment. The results of this study may help to clarify the effectiveness of those combined interventions to counteract muscle wasting and other symptoms of cancer cachexia.

NCT ID: NCT03150381 Active, not recruiting - Cancer Clinical Trials

Promoting Weight-Loss in African American Cancer Survivors in the Deep South

DSNCARES
Start date: May 1, 2012
Phase: N/A
Study type: Interventional

This study tests evidence-based strategies for weight loss among overweight and obesity cancer survivors and family members in rural Alabama.

NCT ID: NCT03148418 Not yet recruiting - Cancer Clinical Trials

A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Start date: August 5, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This is an open-label, multicenter, non-randomized extension study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be according to the respective parent study. Study treatment in the extension study can continue until disease progression or beyond if the participant continues to derive clinical benefit in the judgment of the investigator and if allowed by the parent study or local prescribing information, death, withdrawal of study consent, unacceptable toxicity, pregnancy, participant non-compliance, or study termination by the Sponsor, whichever occurs first.

NCT ID: NCT03146806 Not yet recruiting - Pain Clinical Trials

Intranasal (NAS) Ketamine for Cancer Pain

Start date: July 1, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to determine the safety, feasibility, and utility of intranasal (NAS) ketamine in persistent uncontrolled cancer related pain. In this prospective clinical trial the researchers will investigate the use of NAS ketamine in patients with pain related to cancer or cancer treatment. The researchers plan to enroll at least 15 patients meeting inclusion/exclusion criteria, to achieve a minimum of 10 patients who complete the study. Participants will be recruited from the supportive oncology clinic, oncology clinics, the pain clinic and Acute Pain Service at Emory. Participants will be asked to return to the Phase I unit of the Winship Cancer Building C for a total of 5 study visits, each two to five days apart. During these visits participants will complete questionnaires, have blood samples drawn and will have study medication administered to them in escalating doses. For safety monitoring participants will be contacted by telephone 14 days after the last dose of medication administered.

NCT ID: NCT03145012 Not yet recruiting - Cancer Clinical Trials

Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity

Start date: May 15, 2017
Phase: Phase 4
Study type: Interventional

The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.

NCT ID: NCT03142204 Recruiting - Cancer Clinical Trials

[18F]FAraG (VisAcT) PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy

Start date: May 2017
Phase: Phase 1
Study type: Interventional

This is a Phase 1 study is to visualize biodistribution of a PET tracer called [18F]F-AraG (VisAcT) in cancer patients expected to undergo immunotherapy.